Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.
Authors
Dutton, SFerry, D
Blazeby, J
Abbas, H
Dahle-Smith, A
Mansoor, Was
Thompson, J
Harrison, M
Chatterjee, Anirban
Falk, S
Garcia-Alonso, A
Fyfe, David W
Hubner, Richard A
Gamble, T
Peachey, L
Davoudianfar, M
Pearson, S
Julier, P
Jankowski, J
Kerr, R
Petty, R
Affiliation
Oxford Clinical Trials Research Unit and Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Botnar Research Centre, Oxford, UK.Issue Date
2014-07
Metadata
Show full item recordAbstract
Evidence is scarce for the effectiveness of therapies for oesophageal cancer progressing after chemotherapy, and no randomised trials have been reported. We aimed to compare gefitinib with placebo in previously treated advanced oesophageal cancer.Citation
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. 2014, 15 (8):894-904 Lancet OncolJournal
The Lancet OncologyDOI
10.1016/S1470-2045(14)70024-5PubMed ID
24950987Type
ArticleLanguage
enISSN
1474-5488ae974a485f413a2113503eed53cd6c53
10.1016/S1470-2045(14)70024-5
Scopus Count
Collections
Related articles
- Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial.
- Authors: Zhang L, Ma S, Song X, Han B, Cheng Y, Huang C, Yang S, Liu X, Liu Y, Lu S, Wang J, Zhang S, Zhou C, Zhang X, Hayashi N, Wang M, INFORM investigators
- Issue date: 2012 May
- Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
- Authors: Catenacci DVT, Tebbutt NC, Davidenko I, Murad AM, Al-Batran SE, Ilson DH, Tjulandin S, Gotovkin E, Karaszewska B, Bondarenko I, Tejani MA, Udrea AA, Tehfe M, De Vita F, Turkington C, Tang R, Ang A, Zhang Y, Hoang T, Sidhu R, Cunningham D
- Issue date: 2017 Nov
- Gefitinib for advanced non-small cell lung cancer.
- Authors: Sim EH, Yang IA, Wood-Baker R, Bowman RV, Fong KM
- Issue date: 2018 Jan 16
- Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
- Authors: Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, von Pawel J, Gottfried M, Bondarenko I, Liao M, Gann CN, Barrueco J, Gaschler-Markefski B, Novello S, LUME-Lung 1 Study Group
- Issue date: 2014 Feb
- Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study.
- Authors: Xu J, Kato K, Raymond E, Hubner RA, Shu Y, Pan Y, Park SR, Ping L, Jiang Y, Zhang J, Wu X, Yao Y, Shen L, Kojima T, Gotovkin E, Ishihara R, Wyrwicz L, Van Cutsem E, Jimenez-Fonseca P, Lin CY, Wang L, Shi J, Li L, Yoon HH
- Issue date: 2023 May